Investing.com -- AstraZeneca (LON: AZN ) (ST: AZN) shares fell more than 3% Tuesday after the drugmaker missed first-quarter revenue expectations, with underperformance in key cancer and respiratory ...

Viatris' generic of Symbicort (budesonide and formoterol fumarate dihydrate) – developed by Viatris in collaboration with 3M spin-off company Kindeva Drug Delivery and called Breyna – has been ...

A US court has upheld AstraZeneca’s patents on its respiratory drug Symbicort, blocking cheaper competition for the ageing blockbuster. The US District Court for the Northern District of West ...

SIGNIFICANT EVENTS DURING 1 JANUARY - 31 MARCH 2025Iconovo and Lonza have entered a collaboration to develop spray-dried formulations of an intranasal biologic drug for Iconovo's proprietary intranasa ...

AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, are expected to have driven the company's top line.

The Zacks Consensus Estimate for Symbicort is $772 million, while our model estimate is $767.2 million. Sales of AstraZeneca’s major legacy drugs have been declining due to rising generic ...

Farxiga, a drug that originally entered diabetes therapy ... The situation in respiratory therapy is ambiguous: Symbicort is losing ground, but the launch of Tezspire gives AstraZeneca a chance ...

The drug is injected under the skin of your thigh ... such as budesonide/formoterol (Symbicort). Talk with your doctor if you have questions about using your rescue inhaler during your Nucala ...

Revenues increased across all segments, with sales of most of the key drugs, including Tagrisso, Fasenra, Farxiga, Lynparza and Symbicort, beating estimates. AstraZeneca raised its sales and ...